Summary & Overview
HCPCS J3300: Triamcinolone Acetonide Injection, Preservative-Free, 1 mg
HCPCS Level II code J3300 denotes a 1 mg preservative-free injection of triamcinolone acetonide, a corticosteroid commonly used for localized anti-inflammatory therapy. Nationally, this code matters because it identifies a specific, preservative-free injectable medication formulation that can affect billing, clinical choice, and payer coverage policies across outpatient settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of the code’s clinical purpose and typical settings of use, plus what to expect when evaluating coverage and billing practices for this medication formulation. The publication outlines benchmarks and common billing practices, highlights policy and coverage considerations affecting injectable corticosteroids, and summarizes where clinical context intersects with payer rules.
This summary equips revenue cycle teams, clinicians, and policy analysts with a focused reference on HCPCS Level II code J3300, clarifying the service it represents, typical sites of service, and the payers most relevant for national billing and coverage discussions. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J3300 represents an injection of triamcinolone acetonide, preservative free, 1 mg. The service is a medication administration for a corticosteroid preparation provided as a single-dose, preservative-free injectable formulation.
Service Type: Drug administration (injectable corticosteroid)
Typical Site of Service: Outpatient clinics, physician offices, ambulatory surgical centers, and other outpatient infusion or injection settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 56-year-old patient with a history of chronic allergic rhinitis presents to an otolaryngology clinic for intranasal steroid therapy. The clinician decides to administer an intranasal injection of preservative-free triamcinolone acetonide (J3300, 1 mg) for targeted control of sinonasal inflammation after inadequate response to topical sprays. The workflow includes verification of indications and allergies, informed consent, medication preparation (preservative-free vial or syringe), site identification (nasal mucosa or peri-nasal submucosal tissue depending on indication), local topical anesthesia as needed, aseptic technique, administration of the J3300 injection, post-procedure observation for immediate adverse reactions (5–15 minutes), documentation of lot number and amount of drug used, and scheduling follow-up for efficacy and potential systemic effects. Typical site of service is an ambulatory clinic or office-based procedure room. Patient monitoring includes assessment for bleeding, vasovagal response, potential steroid-related effects, and instructions for delayed adverse event reporting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of a single-dose preservative-free vial or syringe is discarded after administration and payer requires reporting of discarded medication. |